Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Recent Updates to NCCN Guidelines on MF TreatmentPublished: July 6th 2021 | Updated:
Bone Marrow Transplant for Patients With MFPublished: July 20th 2021 | Updated:
Monitoring Disease Response or Progression in MFPublished: July 6th 2021 | Updated:
Fedratinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Ruxolitinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Primary Myelofibrosis: Trials of InterestPublished: July 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5